WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 24, 2006--DUSA Pharmaceuticals, Inc. (NASDAQ NMS:DUSA), today reported statistically significant interim results from its 80 patient, multicenter Phase II clinical study of photodynamic therapy (PDT) in the treatment of mild to moderate photo-damage (sun induced skin aging) of the face.
The study used DUSA's Levulan(R) (aminolevulinic acid HCl, ALA) Kerastick(R) in combination with either the Company's BLU-U(R) brand blue light ("BLU-U"), an Intense Pulsed Light ('IPL'), or a Long Pulsed Dye Laser ('LPDL'), compared to treatment with the vehicle and the same light source without Levulan. Each patient served as their own control, using a 'split-face' design. Following skin cleansing with an acetone solution, and approximately 60 minutes of drug and/or vehicle incubation, light treatment with a fixed dose was given using one of the three light sources. Up to 3 treatments were given, 3 weeks apart. Interim results were assessed at Weeks 9 and 12. The protocol includes additional follow-up visits scheduled for Weeks 26 and 52.
